Corbus Pharmaceuticals Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Corbus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corbus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Corbus Pharmaceuticals.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.42). The biopharmaceutical company had revenue of $1.23 million for the quarter, compared to analysts' expectations of $3.42 million. Corbus Pharmaceuticals had a negative trailing twelve-month return on equity of 485.45% and a negative net margin of 2,208.06%.
View Corbus Pharmaceuticals' earnings history.

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRBP shares have decreased by 39.8% and is now trading at $2.48.
View which stocks have been most impacted by COVID-19.

9 equities research analysts have issued twelve-month target prices for Corbus Pharmaceuticals' shares. Their forecasts range from $2.50 to $112.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $26.39 in the next year. This suggests a possible upside of 964.1% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Corbus Pharmaceuticals include Kadmon (KDMN), ESSA Pharma (EPIX), ADVANZ PHARMA (CXRXF), Odonate Therapeutics (ODT), Esperion Therapeutics (ESPR), Provention Bio (PRVB), Gossamer Bio (GOSS), OrganiGram (OGI), Pandion Therapeutics (PAND), Rigel Pharmaceuticals (RIGL), AnaptysBio (ANAB), Albireo Pharma (ALBO), Calliditas Therapeutics AB (publ) (CALT), Merus (MRUS) and Atreca (BCEL).
View all of CRBP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include ETF Managers Group LLC (9.64%), BlackRock Inc. (6.21%), Renaissance Technologies LLC (1.14%), Pinnacle Associates Ltd. (1.12%), Northern Trust Corp (0.99%) and Charles Schwab Investment Management Inc. (0.53%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals.

CRBP stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BlackRock Inc., Pinnacle Associates Ltd., Wells Fargo & Company MN, Ikarian Capital LLC, Bank of New York Mellon Corp, Alliancebernstein L.P., and Citigroup Inc..
View insider buying and selling activity for Corbus Pharmaceuticals or view top insider-selling stocks.

CRBP stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, JPMorgan Chase & Co., Squarepoint Ops LLC, Davy Global Fund Management Ltd, Renaissance Technologies LLC, LPL Financial LLC, Vontobel Holding Ltd., and Jefferies Group LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals or or view top insider-buying stocks.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRBP stock can currently be purchased for approximately $2.48.

Corbus Pharmaceuticals has a market capitalization of $208.41 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

Corbus Pharmaceuticals employs 141 workers across the globe.

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Corbus Pharmaceuticals is headquartered at 500 River Ridge Drive, Norwood MA, 02062.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]